Try our beta test site

Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer

This study has been terminated.
(low accrual)
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC Identifier:
First received: November 12, 2002
Last updated: July 17, 2012
Last verified: July 2012

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if capecitabine is more effective than vinorelbine in treating metastatic breast cancer.

PURPOSE: Randomized phase II/III trial to compare the effectiveness of capecitabine with that of vinorelbine in treating women who have metastatic breast cancer that has been previously treated with chemotherapy.

Condition Intervention Phase
Breast Cancer
Drug: capecitabine
Drug: vinorelbine tartrate
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: A Randomized Phase II-III Trial Evaluating the Efficacy of Capecitabine and Vinorelbine in Anthracycline and Taxane Pre-Treated Metastatic Breast Cancer

Resource links provided by NLM:

Further study details as provided by European Organisation for Research and Treatment of Cancer - EORTC:

Enrollment: 47
Study Start Date: September 2002
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
Detailed Description:


  • Compare the response rate in women with previously treated metastatic breast cancer treated with capecitabine vs vinorelbine.
  • Compare the duration of response in patients treated with these drugs.

Phase III Study:

  • Compare overall and progression-free survival in patients treated with these drugs.
  • Compare time to treatment failure in patients treated with these drugs.
  • Compare overall safety of these drugs in these patients.
  • Compare quality of life and clinical benefit response in patients treated with these drugs.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center and taxane resistance (refractory vs resistant vs sensitive).

  • Phase II: Patients are randomized to 1 of 2 treatment arms.

    • Arm I: Patients receive vinorelbine IV on days 1 and 8. Courses repeat every 21 days.
    • Arm II: Patients receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days.

In both arms, treatment continues in the absence of progression or unacceptable toxicity.

If sufficient response rate is determined in phase II, the phase III study is initiated.

  • Phase III: Patients are randomized and receive treatment as in phase II. Quality of life is assessed prior to randomization, at weeks 3, 6, 9, 18, 24, and 30, and then every 12 weeks until disease progression.

Clinical benefit response is assessed daily while patient is on study.

Patients are followed every 6 weeks until disease progression and then every 12 weeks thereafter.

PROJECTED ACCRUAL: A total of 72 patients (36 per treatment arm) will be accrued for phase II of this study and a total of 406-452 patients (203-226 per treatment arm) will be accrued for phase III of this study within 18.5 months.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed breast cancer
  • Metastatic disease
  • Prior treatment with taxanes in the metastatic, adjuvant, or neoadjuvant setting

    • Taxane-resistant disease allowed regardless of duration of prior therapy NOTE: Resistant disease defined as progression during or within 12 weeks after taxane therapy for metastatic disease or a disease-free interval of less than 12 months after neoadjuvant or adjuvant therapy with a taxane
    • Taxane-sensitive disease allowed if at least 4 prior courses were received NOTE: Sensitive disease defined as progression occurring more than 12 weeks after taxane therapy for metastatic disease or more than 12 months after neoadjuvant or adjuvant therapy with a taxane
  • Prior treatment with anthracyclines for metastatic disease or as adjuvant treatment OR medical contraindication to treatment with anthracyclines
  • At least one unidimensionally measurable lesion (phase II study)
  • No CNS metastases
  • Hormone receptor status:

    • Not specified



  • 18 and over


  • Female

Menopausal status

  • Not specified

Performance status

  • Karnofsky 70-100%

Life expectancy

  • Not specified


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than 1.25 times upper limit of normal (ULN)
  • Transaminases no greater than 2.5 times ULN (5 times ULN if liver metastases present)


  • Creatinine clearance greater than 50 mL/min


  • No symptomatic ventricular arrhythmias
  • No clinically significant congestive heart failure
  • No clinical or ECG evidence of myocardial infarction within the past 12 months
  • No significant coronary artery disease


  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No prior malignancy within the past 5 years except contralateral breast cancer, nonmelanoma skin cancer, and adequately treated carcinoma in situ of the cervix
  • No known or prior sensitivity to fluoropyrimidines, including fluorouracil
  • No pre-existing grade 2 or greater neurotoxicity
  • No known malabsorption or upper gastrointestinal abnormalities that would affect absorption of study drug
  • No psychological, familial, sociological, or geographical condition that would preclude study compliance


Biologic therapy

  • No concurrent biologic therapy


  • See Disease Characteristics
  • No more than 2 prior chemotherapy lines for metastatic disease
  • No prior capecitabine, vinca alkaloids, or continuous fluorouracil
  • No other concurrent chemotherapy

Endocrine therapy

  • Prior hormonal therapy allowed
  • No concurrent hormonal therapy


  • No concurrent radiotherapy


  • Not specified


  • Bisphosphonate therapy for treatment and prevention of bony metastases allowed if initiated prior to study
  • No other concurrent investigational treatment
  • No concurrent brivudine with capecitabine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00049660

Ziekenhuis Network Antwerpen Middelheim
Antwerp, Belgium, 2020
Institut Jules Bordet
Brussels, Belgium, 1000
Universitair Ziekenhuis Antwerpen
Edegem, Belgium, B-2650
Algemeen Ziekenhuis Sint-Augustinus
Wilrijk, Belgium, 2610
Institut Bergonie
Bordeaux, France, 33076
Centre Henri Becquerel
Rouen, France, 76038
Klinikum Nuernberg - Klinikum Sued
Nurberg, Germany, 90471
Institute of Oncology - Ljubljana
Ljubljana, Slovenia, Sl-1000
United Kingdom
Cancer Research Centre at Weston Park Hospital
Sheffield, England, United Kingdom, S1O 2SJ
Western General Hospital
Edinburgh, Scotland, United Kingdom, EH4 2XU
Beatson Oncology Centre
Glasgow, Scotland, United Kingdom, G11 6NT
Western Infirmary
Glasgow, Scotland, United Kingdom, G11 6NT
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Study Chair: Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute
Study Chair: Chris Twelves, MD, BMedSci, FRCP University of Glasgow
  More Information

Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC Identifier: NCT00049660     History of Changes
Other Study ID Numbers: EORTC-10001-160010
Study First Received: November 12, 2002
Last Updated: July 17, 2012

Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
stage IV breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators processed this record on March 28, 2017